Preclinical studies enable evaluation of drug candidates for both efficacy and safety within biological model systems. Physiological relevance of the models used can closely mimic biochemical pathways, metabolism, and physiology of human. Hence, primary cells, 3D cell culture / tissues, and cell-based assays comprise relevant model systems.
The webinar will focus on preclinical studies within physiological context to better understand the complexity of diseases within the host as well as efficacy and safety of therapeutic intervention.
Firstly, Dr. Seyoum Ayehunie, Vice President, Scientific Research and Development, MatTek Corporation, will discuss the functionality and limitations of a novel in vitro 3D primary human cell-based tissue model for drug toxicity and efficacy studies. Dr. Hyelim Cho, Group Lead, Immunogenicity, Global DMPK Oncology and Rare Diseases, Takeda Pharmaceuticals, will then explain why developing a predictive pre-clinical assay is key to success in immuno-oncology drug development. This will be followed by a live Q&A session, offering you the chance to pose questions to our expert speakers.
Key Learning Objectives: